AFX2内移植物联合主动脉袖套使用的中期结局
本研究纳入日本24家机构2017年4月至2018年3月间使用AFX2主体联合主动脉袖套行腹主动脉瘤腔内修复术(EVAR)的175例病例,分析3年中期结局。3年总生存率85.8%、免于动脉瘤相关死亡率99.3%、免于再干预率87.3%;作者认为中期结局可接受,但存在可能引起未来IIIa型内漏的侧向移位,需密切监测。
要点
- 3年总生存率85.8%、免于动脉瘤相关死亡率99.3%、免于再干预率87.3%
- 无院内死亡,3年分析128例,I型内漏3例、IIIa型1例、IIIb型3例,均无瘤囊扩张
- 5例移位中1例主动脉袖套移位表现为Ia型内漏,4例侧向移位中1例表现为IIIa型内漏
核心结论
- 作者认为,考虑到I型和III型内漏的发生率,AFX2联合主动脉袖套的中期结局可接受。
- 但存在可能引起未来IIIa型内漏的侧向移位病例;AFX2联合主动脉袖套使用时,需密切监测内移植物变形及包括III型内漏在内的后续不良事件。
研究设计与样本
- 研究为多机构病例系列,招募2017年4月至2018年3月间使用AFX2联合主动脉袖套至少5例的日本机构。
- 共分析24家机构的175例病例,收集患者背景(含解剖因素)、手术所见、装置组件变异及EVAR后3年中期结局。
- 各机构登记的I型、III型内漏及移位病例的计算机断层扫描(CT)数据送至研究者所在部门核实。
主要发现
- 患者平均年龄74.6 ± 8.1岁,48例(27%)为囊状动脉瘤。
- 梭形与囊状腹主动脉瘤平均直径分别为50.5 ± 5.8 mm和43.5 ± 8.9 mm。
- 无院内死亡;分析128例的3年数据(含CT图像),3年总生存率、免于动脉瘤相关死亡率、免于再干预率分别为85.8%、99.3%、87.3%。
- I型、IIIa型、IIIb型内漏分别为3例、1例、3例,均无瘤囊扩张;5例移位中1例主动脉袖套移位表现为Ia型内漏,4例侧向移位中1例表现为IIIa型内漏。
- 3年瘤囊回缩率与增大率在梭形组分别为41.4%和20.5%,在囊状组分别为44.2%和16.7%;近端瘤颈直径从EVAR前20.8 ± 2.7 mm略增至修复后22.2 ± 4.6 mm。
临床怎么用
- 作者建议,AFX2联合主动脉袖套使用时需密切监测内移植物变形及包括III型内漏在内的后续不良事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type III endoleaks after endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs) with the Endologix unibody endograft remain a major concern, despite fabric, system, and instructional updates. The purpose of this study was to examine real-world outcomes of repairing AAAs using the current version of the AFX2 main body in combination with an aortic cuff, specifically focusing on type III endoleaks and morphological changes of the endograft. METHODS: We recruited facilities in Japan that used AFX2 combined with an aortic cuff for at least five cases between April 2017 and March 2018. A total of 175 cases in 24 facilities were analyzed. Patients' background information, including anatomic factors, operative findings, device component variations, and midterm outcomes at 3 years after the EVAR were collected. The data on computed tomography scans from cases registered as types I and III endoleaks and migration from each institute were sent to our department for verification. RESULTS: The mean patient age was 74.6 ± 8.1 years, and 48 cases (27%) were saccular aneurysms. The mean fusiform and saccular AAA diameters were 50.5 ± 5.8 mm and 43.5 ± 8.9 mm, respectively. No in-hospital deaths occurred. Data at 3 years, including computed tomography images, of 128 cases were analyzed. Overall survival, freedom from aneurysm-related mortality, and freedom from reintervention rates at 3 years were 85.8%, 99.3%, and 87.3%, respectively. There were three, one, and three cases of types I, IIIa, and IIIb endoleaks without sac dilatations, respectively. Among five migration cases, one case of aortic cuff migration presented as a type Ia endoleak, and four cases demonstrated sideways displacement, one of which presented as a type IIIa endoleak. The sac regression and enlargement rates at 3 years were 41.4% and 20.5% in the fusiform group and 44.2% and 16.7% in the saccular group, respectively. The proximal neck diameter slightly increased from 20.8 ± 2.7 mm before the EVAR to 22.2 ± 4.6 mm after the repair. CONCLUSIONS: Midterm outcomes of the AFX2 used in combination with an aortic cuff were acceptable, considering the rates of types I and III endoleaks. However, there were cases of sideways displacement that could cause future type IIIa endoleaks. When the AFX2 is used in combination with an aortic cuff, close surveillance for endograft deformations and subsequent adverse events, including type III endoleaks, is needed.
引用
- Hoshina K, Suhara M, Miyahara K, et al. Midterm outcomes of AFX2 endografts used in combination with aortic cuffs. J Vasc Surg. 2022. PMID: 36113824. doi:10.1016/j.jvs.2022.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。